Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Nyman

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Anticancer Research|September 27, 2015
Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended RadiotherapyGeorg Holgersson, Stefan Bergström, Per Liv, et al.
Acta Oncologica (Stockholm, Sweden)|September 20, 2006
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countriesPia Baumann, Jan Nyman, Ingmar Lax, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2025
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survivalElla A Eklund, Mathilda Orgard, Delice Wallin, et al.
International Archives of Otorhinolaryngology|August 11, 2021
Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on SurvivalLars Axelsson, Erik Holmberg, Jan Nyman, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2011
Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancerGeorg Holgersson, Stefan Bergström, Michael Bergqvist, et al.
Acta Oncologica (Stockholm, Sweden)|July 17, 2012
Swedish Lung Cancer Radiation Study Group: predictive value of age at diagnosis for radiotherapy response in patients with non-small cell lung cancerGeorg Holgersson, Even Hoye, Michael Bergqvist, et al.
Acta Oncologica (Stockholm, Sweden)|September 20, 2006
Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancerEmma Djärv, Jan Nyman, Pia Baumann, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancerKristin Toftaker Killingberg, Tarje Onsøien Halvorsen, Øystein Fløtten, et al.
Acta Oncologica (Stockholm, Sweden)|March 24, 2020
Analysis of early respiratory-related mortality after radiation therapy of non-small-cell lung cancer: feasibility of automatic data extraction for dose-response studiesLouise Stervik, Niclas Pettersson, Jonas Scherman, et al.
The Lancet. Oncology|March 4, 2021
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trialBjørn Henning Grønberg, Kristin Toftaker Killingberg, Øystein Fløtten, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Anticancer Research|September 27, 2015
Effect of Increased Radiotoxicity on Survival of Patients with Non-small Cell Lung Cancer Treated with Curatively Intended RadiotherapyGeorg Holgersson, Stefan Bergström, Per Liv, et al.
Acta Oncologica (Stockholm, Sweden)|September 20, 2006
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countriesPia Baumann, Jan Nyman, Ingmar Lax, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2025
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survivalElla A Eklund, Mathilda Orgard, Delice Wallin, et al.
International Archives of Otorhinolaryngology|August 11, 2021
Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on SurvivalLars Axelsson, Erik Holmberg, Jan Nyman, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2011
Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancerGeorg Holgersson, Stefan Bergström, Michael Bergqvist, et al.
Acta Oncologica (Stockholm, Sweden)|July 17, 2012
Swedish Lung Cancer Radiation Study Group: predictive value of age at diagnosis for radiotherapy response in patients with non-small cell lung cancerGeorg Holgersson, Even Hoye, Michael Bergqvist, et al.
Acta Oncologica (Stockholm, Sweden)|September 20, 2006
Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancerEmma Djärv, Jan Nyman, Pia Baumann, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2022
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancerKristin Toftaker Killingberg, Tarje Onsøien Halvorsen, Øystein Fløtten, et al.
Acta Oncologica (Stockholm, Sweden)|March 24, 2020
Analysis of early respiratory-related mortality after radiation therapy of non-small-cell lung cancer: feasibility of automatic data extraction for dose-response studiesLouise Stervik, Niclas Pettersson, Jonas Scherman, et al.
The Lancet. Oncology|March 4, 2021
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trialBjørn Henning Grønberg, Kristin Toftaker Killingberg, Øystein Fløtten, et al.
Pageof 7